EPO published patent application EP4048288A1 for Astellas US LLC's anti-C5 agent targeting dry AMD and geographic atrophy. The application covers nucleic acid compositions (C12N 15/115) with various pharmaceutical formulations (A61K 31/712, A61K 31/7088, A61K 31/713) for ocular administration. This is a standard patent publication under the EPC, designating 31 European contracting states.

Pharmaceutical companies developing complement pathway inhibitors for ophthalmic indications should review this publication for potential freedom-to-operate implications. Patent applicants and competitors in the dry AMD therapeutic space should assess claim scope and prosecution history once the application proceeds. No compliance deadlines apply to this publication notice.